Clinical prospective study to investigate efficacy of WT1 peptide (PepTivator(R))-pulsed dendritic cell vaccination therapy

Clinical prospective study to investigate efficacy of WT1 peptide (PepTivator(R))-pulsed dendritic cell vaccination therapy - Clinical prospective study to investigate efficacy of WT1 peptide (PepTivator(R))-pulsed dendritic cell vaccination therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009447

Enrollment

Registered

2012-12-01

Start date

2012-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant tumor (all HLA types)

Interventions

WT1 peptide(PepTivator(R))-pulsed dendritic cells are injected on day0, day14, day28, day42, day56, day70

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Patients with histologically confirmed malignant tumors (all HLA types) (2)Patients who recognized WT1 expression on tumor tissue (3)Performance Status is 0-2 (4)No serious abnormality in bone marrow, liver, and renal functions (5)Informed consent has been obtained.

Exclusion criteria

Exclusion criteria: Patients who have: (1)Pulmonary fibrosis or interstitial pneumonia, or history or predisposition of them (2)Serious drug allergy (3)Positive for HIV or HTLV-1 (4)Active autoimmune disease (5)Continuous systemic administration of steroids (6)Other cancers (7)Active infections (8)Pregnant or lactating (9)Serious cardiac disease (10)Any reason why, in the opinion of the investigator, the patient should not participate.

Design outcomes

Primary

Measure	Time frame
Immunological responses	—

Secondary

Measure	Time frame
Safety Efficacy	—

Countries

Japan

Contacts

Public ContactHiroshi Ibe

Seta Clinic Group Clinical research center

scrc@j-immunother.com03-5215-0086

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026